In ₹ Crore except Per Share Latest Annual	WOCKPHARMA FY26	BIOCON FY26	SYNGENE FY26	ASTERDM FY26	Peer Average
Valuation — at last close
P/E	146.56×	124.79×	◆ 50.65×	90.20×	88.54× +66%
P/B	6.31×	◆ 1.68×	3.32×	7.69×	4.23× +49%
EV/EBITDA	50.54×	20.42×	◆ 16.09×	38.65×	25.05× +102%
Market Cap	₹31,151 Cr	₹57,043 Cr	₹16,060 Cr	₹35,191 Cr	₹36,098 Cr -14%
Growth
Revenue CAGR 3Y	8.36%	◆ 14.85%	5.40%	-26.99%	-2.25% +472%
Revenue CAGR 5Y	4.49%	◆ 18.96%	11.35%	-11.61%	6.23% -28%
Net Income CAGR 3Y	—	-16.91%	-11.98%	◆ -3.51%	-10.80%
Revenue YoY (latest Q)	◆ 25.88%	10.00%	-8.55%	21.60%	7.68% +237%
Net Income YoY (latest Q)	◆ 199.07%	53.36%	-52.01%	-68.70%	-22.45% +987%
Profitability
EBITDA Margin	19.33%	20.41%	◆ 24.57%	19.41%	21.46% -10%
Net Income Margin	5.90%	2.18%	8.47%	◆ 9.20%	6.62% -11%
Return on Common Equity	4.58%	1.39%	6.62%	◆ 9.70%	5.90% -22%
Return on Capital Employed	6.50%	3.19%	8.54%	◆ 9.90%	7.21% -10%
Return on Assets	2.38%	0.60%	4.57%	◆ 5.80%	3.66% -35%
Credit & Quality
Total Debt/Equity	0.40×	0.40×	◆ 0.00×	0.15×	0.18× +118%
Interest Coverage	2.00×	1.51×	◆ 9.54×	5.18×	5.41× -63%
Scale — latest FY
Revenue / Total Income	₹3,373 Cr	₹16,927 Cr	₹3,739 Cr	₹4,643 Cr	₹8,436 Cr -60%
Net Income	₹199 Cr	₹369 Cr	₹317 Cr	₹427 Cr	₹371 Cr -46%
Total Assets	₹8,615 Cr	₹63,651 Cr	₹7,055 Cr	₹8,112 Cr	₹26,272 Cr -67%
EPS	₹13.12	₹2.82	₹7.87	₹7.53	₹6.07 +116%
Book Value per Share	₹304.94	₹209.94	₹120.11	₹88.31	₹139.45 +119%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.